Form 4: Zivo Bioscience Insider Acquisition by Strome Group

Mark E. Strome and affiliated entities acquired 100,000 shares of Zivo Bioscience, Inc. common stock at $2.00 per share.

Summary

• Mark E. Strome, Strome Investment Management, LP, and Strome Group, Inc. reported the acquisition of 100,000 shares of Zivo Bioscience, Inc. (ZIVO).
• The shares were purchased at a price of $2.00 per share on April 17, 2026.
• The securities are held directly by Strome Mezzanine Fund II, LP, an entity for which the reporting persons share voting and investment power.
• Following this transaction, the reporting persons beneficially own 572,942 shares of Zivo Bioscience common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as it reflects direct capital investment from a major shareholder, suggesting confidence in the company's current valuation and future prospects.

Positives

• Significant insider/major shareholder confidence demonstrated by the purchase of 100,000 shares.
• The acquisition price of $2.00 per share provides a clear market valuation reference point for investors.

Negatives

• None identified in this filing.

Risks

• Concentration of ownership among affiliated entities may influence corporate governance and strategic direction.
• The reporting persons disclaim beneficial ownership for purposes of Section 16, which is a standard legal precaution but highlights the complexity of the ownership structure.

Future Outlook

The filing does not provide forward-looking operational guidance, as it is a disclosure of a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider buying, particularly from 10% owners or institutional affiliates, is often viewed by the market as a signal of long-term conviction in the company's underlying technology or pipeline development.

Comparison to Industry Standards

• The transaction is consistent with standard SEC reporting requirements for major shareholders.
• The purchase price of $2.00 per share aligns with typical private placement or secondary market activity for small-cap biotechnology firms.

Related Party Transactions

• The acquisition was made by Strome Mezzanine Fund II, LP, which is managed by Strome Investment Management, LP, with Strome Group, Inc. as the general partner, and Mark E. Strome as the President and CEO.

Stakeholder Impact

• Shareholders may view the increased stake by a major investor as a stabilizing factor for the company's capital structure.

Next Steps

• Continued monitoring of SEC filings for further changes in beneficial ownership or additional capital raising activities.

Key Dates

Recommendation

While insider buying is a positive indicator, this filing represents a routine disclosure of ownership change rather than a fundamental shift in business operations; investors should maintain a hold position while awaiting further clinical or commercial milestones.

Keywords

Zivo Bioscience, ZIVO, Insider Trading, Form 4, Strome Investment Management, Equity Acquisition